P J Bastian1, M Nakayama, A M De Marzo, W G Nelson. 1. The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA. patrick.bastian@gmx.de
Abstract
BACKGROUND: Prostate cancer is the most commonly diagnosed cancer in men in Europe and North America. Despite its high prevalence, the molecular mechanism of its underlying development and progression is poorly understood. Many studies have revealed multiple molecular alterations during prostate cancer carcinogenesis. GSTP1 CpG island hypermethylation is one of the molecular changes that occur during carcinogenesis. METHODS: We evaluated the role of GSTP1 CpG island hypermethylation in prostatic cancers and discussed its possible role as a molecular biomarker of prostate cancer. RESULTS: Studies haven shown that GSTP1 CpG island hypermethylation is present in about 90% of prostatic carcinomas. The DNA alteration was also detectable in body fluids such as blood, urine, ejaculate, or prostatic secretions. One study showed hypermethylation in histologically unsuspicious lymph nodes in surgical specimens in patients with biochemical PSA (prostate-specific antigen) recurrence. Additionally, it is possible to distinguish between normal prostatic tissue, benign prostatic hyperplasia, and prostate cancer. CONCLUSIONS: The detection of GSTP1 CpG island hypermethylation serves as a molecular marker in prostate cancer screening, detection, and diagnosis. It may even provide information on prostate cancer prognosis. However, prospective trials to evaluate its predictive value are necessary.
BACKGROUND:Prostate cancer is the most commonly diagnosed cancer in men in Europe and North America. Despite its high prevalence, the molecular mechanism of its underlying development and progression is poorly understood. Many studies have revealed multiple molecular alterations during prostate cancer carcinogenesis. GSTP1 CpG island hypermethylation is one of the molecular changes that occur during carcinogenesis. METHODS: We evaluated the role of GSTP1 CpG island hypermethylation in prostatic cancers and discussed its possible role as a molecular biomarker of prostate cancer. RESULTS: Studies haven shown that GSTP1 CpG island hypermethylation is present in about 90% of prostatic carcinomas. The DNA alteration was also detectable in body fluids such as blood, urine, ejaculate, or prostatic secretions. One study showed hypermethylation in histologically unsuspicious lymph nodes in surgical specimens in patients with biochemical PSA (prostate-specific antigen) recurrence. Additionally, it is possible to distinguish between normal prostatic tissue, benign prostatic hyperplasia, and prostate cancer. CONCLUSIONS: The detection of GSTP1 CpG island hypermethylation serves as a molecular marker in prostate cancer screening, detection, and diagnosis. It may even provide information on prostate cancer prognosis. However, prospective trials to evaluate its predictive value are necessary.
Authors: C Jerónimo; H Usadel; R Henrique; J Oliveira; C Lopes; W G Nelson; D Sidransky Journal: J Natl Cancer Inst Date: 2001-11-21 Impact factor: 13.506
Authors: X Lin; M Tascilar; W H Lee; W J Vles; B H Lee; R Veeraswamy; K Asgari; D Freije; B van Rees; W R Gage; G S Bova; W B Isaacs; J D Brooks; T L DeWeese; A M De Marzo; W G Nelson Journal: Am J Pathol Date: 2001-11 Impact factor: 4.307
Authors: C I Suh; T Shanafelt; D J May; K R Shroyer; J B Bobak; E D Crawford; G J Miller; N Markham; L M Glode Journal: Mol Cell Probes Date: 2000-08 Impact factor: 2.365
Authors: P J Bastian; J Ellinger; D Schmidt; N Wernert; A Wellmann; S C Müller; A von Rücker Journal: Eur J Med Res Date: 2004-11-29 Impact factor: 2.175
Authors: A Denda; Y Mori; Y Yokose; K Uchida; Y Murata; T Makino; M Tsutsumi; Y Konishi Journal: Chem Biol Interact Date: 1985-12-31 Impact factor: 5.192
Authors: Donkena Krishna Vanaja; Mathias Ehrich; Dirk Van den Boom; John C Cheville; R Jeffrey Karnes; Donald J Tindall; Charles R Cantor; Charles Y F Young Journal: Cancer Invest Date: 2009-06 Impact factor: 2.176
Authors: P J Bastian; J Ellinger; A von Rücker; S C Müller; S Yegnasubramanian; W G Nelson; C G Stief Journal: Urologe A Date: 2008-09 Impact factor: 0.639
Authors: Jens Kollermann; Carsten Kempkensteffen; Burkhard Helpap; Mark Schrader; Hans Krause; Markus Muller; Kurt Miller; Martin Schostak Journal: BMC Urol Date: 2006-06-27 Impact factor: 2.264